Is Zoetis (ZTS) overvalued or fairly valued?

MarketChacha shows Zoetis's valuation in context — a trailing P/E of about 12.6, a forward P/E of about 12.2, a price-to-book of about 10.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Zoetis's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.09×) from reported figures — education, not a rating.

What is Zoetis's revenue?

Zoetis reported revenue of $9.5B for FY2025, with net profit of $2.7B, per official filings.

What is the share price of Zoetis (ZTS)?

Zoetis last traded at $79.94 (+0.4% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Zoetis

ZTS · NYSE · Healthcare · United States

Snapshot

TickerZTS

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees14,500

HeadquartersParsippany, United States

Websitewww.zoetis.com

Filings tracked21

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Who owns it

Insiders0.2%
Institutions99.8%
Public & other0.0%

2,029 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.54%
Vanguard Capital Management LLC6.30%
Vanguard Portfolio Management LLC5.77%
State Street Corporation4.76%
State Farm Mutual Automobile Insurance Co3.85%
Geode Capital Management, LLC3.22%
Wellington Management Group, LLP2.28%
Morgan Stanley2.15%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.09×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend27.4% → 28.2%

Margin has held broadly steady over the period — stable profitability.

Return on equity80.2%

Latest ROE of 80.2% — capital is generating a healthy return.

Growth qualityrev 5% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $2.2B · EPS 1.31

Est. earnings growth -11.4%

Next fiscal year

Rev $9.5B · EPS 6.55

Est. earnings growth +5.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$9.5B

Net margin

28.2%

ROE

80.2%

Revenue CAGR (2y)

+5.3%

Profit CAGR (2y)

+6.8%

EPS (FY2025)

6.02

Net profit (FY2025)

$2.7B

Ask MarketChacha about ZTS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$9.5B	$2.7B	6.02	28.2%	80.2%
FY2024	$9.3B	$2.5B	5.47	26.9%	52.1%
FY2023	$8.5B	$2.3B	5.07	27.4%	46.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$2.5B	$691.0M	1.65	28.0%
2026Q1	$2.3B	$601.0M	1.42	26.6%
2025Q3	$2.4B	$721.0M	1.63	30.0%
2025Q2	$2.5B	$726.0M	1.63	29.3%
2025Q1	$2.2B	$602.0M	1.34	27.4%
2024Q3	$2.4B	$682.0M	1.50	28.6%
2024Q2	$2.4B	$624.0M	1.37	26.4%
2024Q1	$2.2B	$599.0M	1.31	27.4%
2023Q3	$2.2B	$596.0M	1.29	27.7%
2023Q2	$2.2B	$671.0M	1.45	30.8%
2023Q1	$2.0B	$552.0M	1.19	27.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change, Exhibits
SEC8/6/2026material
8-K — Executive/director change, Shareholder vote results
SEC5/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Results of operations, Exhibits
SEC2/12/2026material
10-K filing
SEC2/12/2026
8-K — Reg FD disclosure, Exhibits
SEC2/5/2026material

2025

8-K — Material agreement, Material financial obligation, Unregistered equity sale, Reg FD disclosure, Exhibits
SEC12/18/2025material
8-K — Reg FD disclosure, Exhibits
SEC12/11/2025material
8-K — Other events, Exhibits
SEC12/2/2025material
8-K — Results of operations, Exhibits
SEC11/4/2025material
10-Q filing
SEC11/4/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC10/28/2025material
8-K — Reg FD disclosure, Exhibits
SEC10/9/2025material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC8/27/2025material
8-K — Other events, Exhibits
SEC8/18/2025material
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q filing
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.